BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers

13 4 2021 07:40:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases

13 4 2021 07:37:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

13 4 2021 07:35:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research

13 4 2021 07:32:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients

13 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 4 2021 16:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

31 3 2021 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting

20 3 2021 11:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 3 2021 16:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

28 2 2021 08:00:00 提供 Nasdaq GlobeNewswire